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Abstract
Background: Epstein-Barr virus (EBV) is the causative agent of immunosuppression associated
lymphoproliferations such as post-transplant lymphoproliferative disorder (PTLD), AIDS related
immunoblastic lymphomas (ARL) and immunoblastic lymphomas in X-linked lymphoproliferative
syndrome (XLP). The reported overall mortality for PTLD often exceeds 50%. Reducing the
immunosuppression in recipients of solid organ transplants (SOT) or using highly active
antiretroviral therapy in AIDS patients leads to complete remission in 23–50% of the PTLD/ARL
cases but will not suffice for recipients of bone marrow grafts. An additional therapeutic alternative
is the treatment with anti-CD20 antibodies (Rituximab) or EBV-specific cytotoxic T-cells.
Chemotherapy is used for the non-responding cases only as the second or third line of treatment.
The most frequently used chemotherapy regimens originate from the non-Hodgkin lymphoma
protocols and there are no cytotoxic drugs that have been specifically selected against EBV induced
lymphoproliferative disorders.
Methods: As lymphoblastoid cell lines (LCLs) are well established in vitro models for PTLD, we
have assessed 17 LCLs for cytotoxic drug sensitivity. After three days of incubation, live and dead
cells were differentially stained using fluorescent dyes. The precise numbers of live and dead cells
were determined using a custom designed automated laser confocal fluorescent microscope.
Results: Independently of their origin, LCLs showed very similar drug sensitivity patterns against
29 frequently used cytostatic drugs. LCLs were highly sensitive for vincristine, methotrexate,
epirubicin and paclitaxel.
Conclusion: Our data shows that the inclusion of epirubicin and paclitaxel into chemotherapy
protocols against PTLD may be justified.
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Development of malignant B-cell lymphomas after organ
transplantation is a significant complication arising as a
side effect of the immunosuppression required for suc-
cessful graft survival. The oncogenic Epstein-Barr virus
(EBV) is the etiologic agent in the posttransplant lympho-
proliferative disorder (PTLD) and AIDS related immuno-
blastic lymphomas (ARL) [1]. The reported overall
mortality for PTLD often exceeds 50% [2,3]. The progno-
sis for PTLDs occurring after bone marrow transplantation
is even worse [4,5]. Male patients with the rare inherited
X-linked lymphoproliferative syndrome, showing specific
immune defect against EBV infection, also often succumb
to EBV induced malignant lymphomas [6].
EBV is a ubiquitous human herpesvirus that persists for
life. Primary EBV infection can lead to mononucleosis
(IM) in adolescence and in adults, manifested by a mas-
sive expansion of B cells. EBV-encoded transformation-
associated proteins drive the proliferation of B lymphob-
lasts in IM, in PTLDs and in immunodeficiency syn-
drome-associated immunoblastic lymphomas. The EBV
transformed cells express nine latency-associated viral
proteins: EBNA1-6, LMP-1, -2A and -2B. This latency pro-
gram is referred to as the type III latency. The same latency
program is present in the in vitro proliferating lymphob-
lastoid cell lines (LCLs), generated by infection of normal
human B cells with EBV. The fraction of B cells that is sus-
ceptible to in vitro transformation can be anything
between 10% and 100% [7].
EBV drives the proliferation of human B cells in vitro and
during primary infection in vivo. Strong T cell-mediated
immune responses have been documented against EBV
encoded latent proteins and a wide range of HLA class I
molecules with EBV originated peptide epitopes have
been identified [8-10]. EBV associated lymphoprolifera-
tive disease can develop only in the absence of a compe-
tent cytotoxic T cell immune surveillance. EBV associated
lymphoproliferative disease may disappear upon treat-
ment restoring the immune response against EBV-infected
B cells.
Historically LCLs were often regarded as non-tumorigenic
in immunosupressed mice upon subcutaneous inocula-
tion, especially in comparison with highly tumorigenic
Burkitt's lymphomas. However intraperitoneal inocula-
tion regularly leads to development of generalized lym-
phomas with multiorgan involvement. SCID mice
inoculated intraperitoneally with peripheral blood lym-
phocytes (PBL) from EBV-seropositive donors or with
human LCLs, develop EBV-induced human lymphoprolif-
erations within a few weeks. These lymphomas are classi-
fied as immunoblastic lymphomas, often with
plasmacytoid features [11]. Histologically the PBL derived
human-SCID tumors very much resemble the EBV posi-
tive large cell lymphomas of immunosuppressed patients
[12]. The tumors of the immunocompromised patients or
the experimental tumors growing in immunodefective
mice as well as the in vitro growing LCLs show very similar
phenotypes. All three express the same spectrum of cell
surface markers, B cell activation antigens and adhesion
molecules. All three have normal karyotype and show
identical viral gene expression patterns.
The risk of PTLD has been found to depend upon the type
of the transplanted organ, the immunosuppressive regi-
men, the age, the underlying illness and the EBV status of
the recipient at the time of transplantation. The estimated
incidence of PTLD ranges from 1–4% after renal trans-
plantation to 19% after intestinal transplantation. In
bone marrow allograft recipients PTLD is relatively
uncommon (1%) [13,14] except for when certain high
risk regimes, such as in vitro T-cell depletion (TCD) are
used, when the risk may rise to 30%[4,15] PTLD follow-
ing allogenic stem cell transplantation usually derives
from donor lymphocytes. The risk of PTLD is greater if the
host is EBV-seronegative at the time of transplantation
and/or if there is a mismatch between the donor and
recipient HLA types [1].
No controlled studies have been performed in the man-
agement of PTLD and most of the recommendations for
therapy come from small cohorts at single institutions [1].
The relative importance of T cell impairment, EBV and
clonal proliferation has led to the following strategies:
reduction of immunosuppression or prophylactic restora-
tion of T-cell immunity [16], antiviral therapy and chem-
otherapy. Reducing the immunosuppression leads to
complete and durable remission of PTLD [17] for 23–
50% of patients after organ transplantation (SOD) but
will not be efficient in the BMT setting. Reduction of
immunosuppression is frequently the first therapeutic
step, and patients who have had organ rejection have a
much poorer prognosis.
For secondary EBV lymphomas post BMT none of the
above regimens will suffice, except when specifically
restoring EBV specific immunity [16]. Anti-B-cell mono-
clonal antibodies are an effective therapy for PTLD. A
combination of anti CD21 and anti-CD24 antibodies
were used. However these antibodies are not commer-
cially available and interest has therefore recently turned
towards Rituximab, a humanized monoclonal antibody
against the pan-B cell marker CD20. The response rate of
Rituximab treatment is 65% with a relapse rate of 18%
[18,19].Page 2 of 12
(page number not for citation purposes)
BMC Cancer 2006, 6:265 http://www.biomedcentral.com/1471-2407/6/265In cases that are not responding to the above mentioned
therapy, chemotherapy is used as the second or third line
of option.
The most frequently used chemotherapy protocols are the
anthracycline based CHOP (cyclophosphamide, doxoru-
bicin, vincristine and prednisolone) and VAPEC-B (doxo-
rubicin, etoposide, cyclophosphamide, methotrexate,
bleomycin, and vincristine) [20]. In the study of Muti et
al. 17 of 40 PTLD patients were treated with a combina-
tion of reduced immunosuppression and chemotherapy
(CHOP, VACOP-B – cyclophosphamide, vincristine, ble-
omycin, prednisolone, with increasing doses of doxoru-
bicin and etoposide- or DHAP -cisplatinum, cytosine-
arabinoside, dexamethasone) [21]. Remission rate for
anthracycline-based combination therapy is 69%.
PTLD patients are exposed to a high mortality risk due to
chemotherapy treatment related toxicity [1].
The side effects of a drug are the limiting factor in deter-
mining the dose. Increasing the dose of a drug leads to a
more frequent appearance of side effects. Chemothera-
peutic agents can also compromise the survival of the
graft. Drugs that are effective even at low doses could
therefore, not only give fewer side effects, but also provide
a better graft survival.
The aim of this study was to find the most effective cyto-
toxic drugs against EBV-induced lymphoproliferations.
We carried out over 6500 cell survival and proliferation
assays, on single cell level, in order to establish the pattern
of in vitro efficacy of the most commonly used cytotoxic
drugs against EBV-transformed lymphoblastoid cells.
Methods
Cell lines and culture conditions
17 lymphoproliferative cell lines (LCLs) were used in the
present study. 980215, 031016, 040113, 051018, JAK, LP,
MIN, AF, GK, FUR, HA, VMB were established by in vitro
infection of normal B lymphocytes, from different healthy
donors, with the B95.8 strain of EBV. These cell lines were
expanded in IMDM (Sigma) medium supplemented with
10% fetal calf serum (FCS). LSspontan is a spontaneous
LCL established from a healthy donor. IARC171 was
established using B95.8 virus infection of normal lym-
phocytes from a patient with Burkitt's lymphoma. TR was
established from B cells of an XLP patient, with deletion
in the SAP gene. The cell line IB4 contains an integrated
EBV genome.
During the time of experiment the LCLs were cultured in
IMDM (Sigma) supplemented with 20% FCS (Sigma),
100 mmol L-glutamine (Sigma) and 80 µg/ml gentamicin
(Sigma). Cell suspensions were grown in a humidified
incubator at 37°C in an atmosphere containing 5% CO2.
Cell counts were adjusted to an optimal concentration of
1 × 106 cells/ml and the cells were fed twice a week. The
absence of mycoplasma contamination was assured by
regular monitoring with Hoechst 33258 staining.
Drugs
For the in vitro drug sensitivity test 29 drugs were used
(summarized in Table 1). All the drugs were dissolved in
50% dimethyl sulfoxide (DMSO) and printed on 384 well
plates, using a high density metal pin array (with 50 nl
replica volumes) in Biomek 2000 fluid dispenser robot
(Beckman). The same robot was used to generate the drug
masterplates containing the triplicates of four different
drug dilutions using a single tip automatic dispenser
head.
The highest drug concentration was selected as the physi-
cochemical maximally achievable drug concentration at
600 times dilution (50 nl drug in 30 µl suspension assay
volume)
The Ratio of Maximum Achieved Plasma Concentration
(RMAPC) was determined for each drug concentration in
order to compare the in vitro tested concentrations to the
in vivo maximally achieved plasma concentration (Cmax)
levels.
RMAPC was calculated according to the following equa-
tion:
RMAPC = in vitro tested concentration/Cmax
In vitro drug sensitivity assay
In vitro drug sensitivity of LCLs was assessed using a 3-day
cell culture on microtiter plates. 28 drugs were tested, each
at 4 different concentrations in triplicates on 384-well
plates (Greiner). Each well was loaded with 30 µl cell sus-
pension containing 3000 cells. After three days of incuba-
tion the live and dead cells were differentially stained
using fluorescent VitalDye (Biomarker, Hungary). The
exact number of live and dead cells was determined using
a custom designed automated laser confocal fluorescent
microscope (a modified Perkin-Elmer UltraView LCI sys-
tem) at the Karolinska Institute visualization core facility
(KIVIF). The images were captured using the computer
program QuantCapture 4.0 and the live and dead cells
were identified and individually counted using the pro-
gram QuantCount 3.0. Both programs were developed at
the KIVIF using OpenLab Automator programming envi-
ronment (Improvision). 15 control wells, that were used
to determine the control cell survival (CCS), contained
cells with only culture medium and 50 nl DMSO without
drugs, 5 wells contained cells with culture medium alone.
Comparing the two types of control wells no toxic effectPage 3 of 12
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Table 1: Used drugs, Cmax, AUC levels
Drug groups Drug name Brand name, company In vitro used 
concentrations 
(µg/ml)
Cmax Value 
(µg/ml) In vivo dose (Cmax) AUC (µg × h/ml) In vivo dose (AUC) Reference
anthracyclines epirubicin Epirubicin Meda, Meda 0.026–1.66 9 120 mg/m2 2.412 90 mg/m2 (Fogli et al. 2002) [23]
daunorubicin Cerubidin®, Aventis Pharma 0.065–4.166 0.49 0.95 mg/kg in 45 min 1.2786 1.5 mg/kg (Andersson et al. 1979) [6]
doxorubicin Doxorubicin Teva, Teva 0.026–1.66 0.93 50 mg/m2 0.82464 50 mg/m2 (Toffoli et al. 2004) [24]
epipodophyllotoxin etoposide Sigma 0.325–20.833 2.5 53 mg/m2/day 5.06 100 mg/m2/day (Minami et al. 1995) [25] (Gruber et al.1995) 
[26]
camptothecins topotecan Hycamtin®, GlaxoSmithKline 0.052–3.33 0.0084 2.3 mg/m2/day 0.0196 1.2 mg/m2/day (Gerrits et al. 1999) [27]
taxanes paclitaxel Taxol, Orifarm 0.078–5 3.38 175 mg/m2 by 3 h 13.49 175 mg/m2 (Fogli et al. 2002) [23]
docetaxel Taxotere®, Aventis Pharma 0.52–33.33 2 60 mg/m2 3.326 85 mg/m2 (Rischin et al. 2002) [28]
vinca alkaloids vincristine Vincristine Mayne, Mayne Pharma 0.0065–0.416 0.37 1.4 mg/m2 0.182 1.32 mg/m2 (Terashi et al. 2000) [29] (Desai et al. 1982) 
[30]
vinblastine Velbe®, STADApharm 0.013–0.833 0.005 1.5 mg/m2 by 24 h 0.218 1.7 mg/m2 (Stewart et al. 1983) [31] (Bates et al.) [32]
vinorelbine Navelbine®, Pierre Fabre 0.13–8.33 0.83 200 mg/week 0.899 80 mg/m2/week (Zhou et al. 1991) [33] (Freyer et al. 2003) 
[34]
platinum analogs carboplatin Carboplatin Mayne, Mayne Pharma 0.13–8.33 0.046 360 mg/m2 348000 360 mg/m2 (Ghazal-Aswad et al. 1996) [35]
oxaliplatin Eloxatin, Sanofi-Synthelabo 0.065–4.166 3.2 130 mg/m2 71.5 130 mg/m2 (Gamelin et al. 1997) [36] (Graham et al. 
2000) [37]
antifolate methotrexate Methotrexate Pharmacia, Pfizer 0.325–20.833 363 8–12 g/m2 13200000 12 g/m2 (Bacci et al. 2006) [38] (Crews et al. 2004) 
[39]
purin antagonists 6-mercaptopurine Sigma 1.085–69.44 2 2.5 mg/kg oral dose 0.2587 85 mg/m2 (Chan et al. 1989) [26]
cladribine Leustatin, Janssen-Cilag 0.013–0.833 0.0356 5 mg/m2 0.1541 5 mg/m2 (Albertioni et al. 1998) [40]
pyrimidine antagonists fluorouracil Fluorouracil Mayne, Mayne Pharma 0.65–41.66 55.4 400 mg/m2 11.59 400 mg/m2 (Casale et al. 2004) [41]
cytarabine Cytarabine Pfizer, Pfizer 1.302–83.33 10.8 3 g/m2 523.4 1 g/m2 (DeAngelis et al. 1992) [42] (Gruber et al. 
1995) [26]
gemcitabine Gemzar, Orifarm 0.781–50 22.3 1000 mg/m2 9.3 1000 mg/m2 (Fogli et al. 2002) [23]
antitumor antibiotics bleomycin Bleomycin Baxter, Baxter 0.39–25* 0.19* 30 IU/day 0.089 8 IU/kg/day (Broughton et al. 1977) [43] (Peng et al.1980) 
[44]
dactinomycin Cosmegen®, MSD 0.006–0.416 0.1 1.5 mg/m2 300 1.5 mg/m2 (Veal et al. 2005) [45]
protease inhibitors bortezomib Velcade®, Janssen-Cilag 0.013–0.833 0.08 1.45 mg/m2 0.0438 1.45 mg/m2 (Papandreou et al. 2004) [46]
MG132 Sigma 0.13–8.33 #
alkylating agents cyclophosphamide Sendoxan, Baxter 0.52–33.33 37.2 50 mg/kg 367 50 mg/kg (Xie et al. 2006) [47]
ifosphamide Holoxan®, Baxter 0.52–33.33 56.63 16 g/m2 in 96 h 1827.7 3 g/m2/day (Wright et al. 1995) [48] (Boddy et al. 1996) 
[45]
chlorambucil Sigma 1.302–83.33 0.49 0.2 mg/m2 0.883 0.2 mg/m2 (GlaxoSmithKline Research Triangle Park) 
[49]
streptozotocin Sigma 0.65–41.66 ¤
miscellaneous asparaginase Asparaginase Medac, Medac 0.065–4.166* 4.48* 10000 IU/m2 0.943 30000 IU/m2 (Ho et al. 1981) [50] (Ylikangas et al. 2002) 
[51]
hydroxyurea Sigma 0.65–41.66 21 18 mg/kg 82.49 15 mg/kg (Gwilt et al. 2003) [52] (Yan et al. 2005) [46]
prednisolone Di-Adreson F Aquosum, Organon 1.56–100 0.325 1 mg/kg/day 1.33 1 mg/kg/day (Rostin et al. 1990) [53]
Cmax: maximum plasma level after administration of the clinical dose of the drug
*In case of bleomycin and asparaginase concentrations are in IU/ml
AUC: area under curve
#: not used in the clinical practice
¤: no data is available
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determined from the average of cell survival of all 17
LCLs.
Results
Comparison of the drug sensitivity pattern of the different 
LCLs
The 17 different LCLs that were tested in the present study
represent a large variety of cells with different origins and
in vitro history. The investigation included cell lines with
several years of continuous in vitro culturing along with
freshly established transformed B-cell cultures of only 3
weeks of age. Many of the lines were transformed by the
B95-8 strain of EBV and some of them were spontaneous
outgrowths driven by the donors own virus. Among the
lines, we had LCLs from healthy donors, from XLP
patients or lines established from the normal B-cells of
Burkitt's lymphoma patients. We tested lines with both
episomal and integrated EBV genome.
Remarkably, the LCLs of different origins showed a very
similar sensitivity pattern against the different drugs. This
phenomenon is illustrated in Figure 1, which summarizes
the survival curves of all 17 LCLs against the four different
concentrations of epirubicin. Each individual thin curve
represents the average of three independent measure-
ments. The thick line is the mean of all curves, the Mean
Cell Survival (MCS). The grey shaded area marks the ±
standard deviation (SD). Figure 2 summarizes the Mean
Cell Survival curve along with the standard deviations for
28 drugs again emphasizing the very similar response of
the different cell lines. The values for MG132 are repre-
sented only in Table 2.
Identification of highly effective and non-effective drugs
The starting concentrations of the dilution series (1×, 4×,
16×, 64×) for the individual drugs were initially deter-
mined based on the solubility of the different agents. To
make the cell survival data comparable with each other,
we first compiled the known Maximum Achieved Plasma
Concentration data (Cmax) for all 28 drugs stated from
the literature (Table 1-column 5). Dividing the actual
drug concentrations in the dilution series with the Cmax
of the particular drug yielded the Ratio of Maximum
Achieved Plasma Concentration (RMAPC). The calculated
values of RMAPC for all the drugs are summarized in
Table 2 along with MCS and ± SD values. Plotting the cell
survival against the RMAPC values allowed a direct com-
parison of the effectiveness of different drugs. Figure 3
shows the comparison of the effectiveness of the members
of three different drug families: the anthracyclines, vinca
alcaloids and taxans. Figure 4 summarizes the mean cell
survival curves for all the drugs along a common RMAPC
axis. Based on their effectiveness on LCLs, we have divided
the drugs into three different groups:
Group 1: The drugs were considered to be highly effective
if the mean cell survival (MCS) was below 30% at RMAPC
0.3 or below that.
Group 2: The drug was partially effective if MCS was under
60% and RMAPC was between 0.3 and 1.
Group 3: The drug was ineffective, e.g. the LCLs were
resistant to the drug, if MCS was above 60% or RMAPC
was above 1.
We found that the four most effective drugs against LCLs
were: vincristine, paclitaxel, methotrexate and epiru-
bicin (Group 1).
Gemcitabin, cytosine-arabinoside, doxorubicin, fluorour-
acil, dactinomycin, docetaxel, daunorubicin, etoposide,
vinorelbine was rated as partially effective (Group 2.)
Most LCLs were resistant to cyclophosphamide, asparagi-
nase, topotecan, oxaliplatin, bleomycin, 6-mercaptopu-
rin, hydroxyurea, cladribine, chlorambucil, carboplatin,
bortezomib, cytarabine, prednisolone and vinblastine
(Group 3). Almost no drug response could be seen with
oxaliplatin, bleomycin, cyclophosphamide, asparaginase,
hydroxyurea and ifosphamide whereas vinblastine, chlo-
rambucil, prednisolone and topotecan were effective, but
only at very high concentrations, well above the maxi-
mum achievable plasma concentrations.
Although the Group 3 drugs were not effective against
LCLs, these drugs show concentration dependent growth
Drug sensitivity pattern of 17 lymphoblastoid cell lines for epirubicinFig re 1
Drug sensitivity pattern of 17 lymphoblastoid cell 
lines for epirubicin. The mean value of survival of LCLs is 
represented by the black curve, ± SD value is marked with 
grey. 1× : highest concentration, 16×: 16 times dilution of the 
highest concentration etc.Page 5 of 12
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Mean values and standard deviations of drug sensitivity of 17 lymphoblastoid cell lines for 28 different cytostatic drugsFigure 2
Mean values and standard deviations of drug sensitivity of 17 lymphoblastoid cell lines for 28 different cyto-
static drugs. y axis: fraction of surviving cells 0–100% x axis: drug dilutions (1× represents the highest concentration).
BMC Cancer 2006, 6:265 http://www.biomedcentral.com/1471-2407/6/265Table 2: The average Mean Cell Survival (MCS) of the 17 LCLs at different drug concentrations, expressed as the Ratio of Maximum 
Achieved Plasma Concentration (RMAPC)
64× dilution 16× dilution 4× dilution 1× no dilution 64× dilution 16× dilution 4× dilution 1× no dilution
Group 1 Vincristine Epirubicin
RMAPC 0.018 0.071 0.282 1.128 RMAPC 0.003 0.012 0.046 0.184
MCS 81.498 46.541 20.776 18.995 MCS 85.206 65.736 29.435 16.306
SD 27.995 25.737 15.258 12.209 SD 15.548 23.394 13.593 11.314
Paclitaxel Methotrexate
RMAPC 0.020 0.081 0.326 1.303 RMAPC 0.001 0.004 0.014 0.057
MCS 48.119 29.999 24.653 23.148 MCS 76.618 44.824 32.924 29.314
SD 28.435 17.418 12.869 13.364 SD 22.796 25.843 15.590 16.455
Group 2 Gemcitabin Dactinomycin
RMAPC 0.035 0.140 0.561 2.242 RMAPC 0.066 0.262 1.050 4.200
MCS 49.354 38.411 27.808 23.784 MCS 86.206 54.700 20.520 16.465
SD 34.718 30.034 16.945 12.153 SD 16.701 22.386 13.642 8.370
5-Flurouracil Vinorelbine
RMAPC 0.012 0.047 0.188 0.752 RMAPC 0.156 0.625 2.501 10.005
MCS 74.861 58.001 42.337 30.505 MCS 82.833 42.823 25.176 24.683
SD 23.686 22.987 21.370 20.645 SD 18.131 23.930 16.506 14.634
Doxorubicin Daunorubicin
RMAPC 0.028 0.112 0.447 1.789 RMAPC 0.133 0.531 2.126 8.502
MCS 82.503 52.477 28.292 11.499 MCS 83.171 61.159 25.940 20.439
SD 21.753 24.867 22.314 10.301 SD 21.886 25.402 23.933 17.961
Etoposide Docetaxel
RMAPC 0.130 0.521 2.083 8.333 RMAPC 0.260 1.042 4.166 16.665
MCS 56.281 35.375 25.315 16.778 MCS 32.990 23.036 23.866 26.331
SD 21.045 19.983 15.497 11.166 SD 22.690 17.587 16.810 19.810
Group 3 Cytarabine 6-Mercaptopurine
RMAPC 0.121 0.482 1.929 7.716 RMAPC 0.543 2.170 8.680 34.720
MCS 87.321 79.450 48.255 40.124 MCS 84.450 78.834 62.325 55.419
SD 17.396 22.850 26.423 26.315 SD 22.147 16.514 29.820 32.858
Oxaliplatin Cladribine
RMAPC 0.020 0.081 0.325 1.301 RMAPC 0.366 1.462 5.850 23.399
MCS 87.951 84.477 83.331 73.511 MCS 102.832 101.241 72.497 52.237
SD 21.010 26.545 21.839 30.744 SD 8.130 11.160 26.804 29.545Page 7 of 12
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RMAPC 0.015 0.058 0.232 0.930 RMAPC 2.646 10.586 42.342 169.370
MCS 92.021 91.570 90.371 82.978 MCS 89.903 71.879 13.225 11.099
SD 13.718 13.222 18.153 15.919 SD 17.578 26.506 10.994 7.527
Cyclophosphamide Topotecan
RMAPC 0.014 0.056 0.224 0.896 RMAPC 6.194 24.777 99.107 396.429
MCS 86.670 93.412 89.498 84.041 MCS 93.897 72.802 23.250 24.784
SD 21.910 18.833 17.832 17.920 SD 19.406 21.275 16.659 21.380
Ifosphamide Carboplatin
RMAPC 0.009 0.037 0.147 0.588 RMAPC 2.814 11.257 45.027 180.108
MCS 92.729 95.906 90.101 88.518 MCS 91.805 79.175 77.962 52.322
SD 16.694 14.965 15.299 16.677 SD 16.670 30.927 22.065 31.295
Hydroxyurea Bleomycin
RMAPC 0.031 0.124 0.496 1.984 RMAPC 2.078 8.311 33.245 132.979
MCS 95.118 96.489 86.340 68.134 MCS 90.007 88.553 82.168 69.803
SD 19.595 13.933 19.759 24.782 SD 19.294 17.678 19.720 16.686
Vinblastine Streptozotocin
RMAPC 2.603 10.413 41.650 166.600 RMAPC no Cmax data was found
MCS 81.507 53.331 28.885 21.323 MCS 95.430 92.335 89.919 87.805
SD 25.921 25.678 17.941 15.889 SD 15.828 18.710 14.094 22.637
Bortezomib MG-132
RMAPC 0.162 0.648 2.590 10.361 RMAPC not used in clinical practice
MCS 93.119 81.671 75.498 28.700 MCS 87.345 96.374 88.097 27.045
SD 13.779 21.572 19.617 26.948 SD 13.980 17.493 16.974 24.310
Prednisolone
RMAPC 4.8 19.23077 76.92308 307.6923
MCS 75.55877 76.25595 62.46537 37.23379
SD 4.647172 11.09091 13.97021 11.65414
Group 1. Highly effective drugs: RMAPC < 0.3; MCS < 30%
Group 2. Partially effective drugs: RMAPC between 0.3 and 1, MCS < 60%
Group 3. Ineffective drugs: RMAPC > 1 or MCS > 60%
SD: standard deviation in mean cell survival
Table 2: The average Mean Cell Survival (MCS) of the 17 LCLs at different drug concentrations, expressed as the Ratio of Maximum 
Achieved Plasma Concentration (RMAPC) (Continued)Page 8 of 12
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(data not shown).
No RMAPC could be determined for streptozocin because
no pharmacokinetical trials with established Cmax
plasma levels were found. RMAPC was also not available
for MG132 because it has not been used clinically. Strep-
tozocin had no effect on survival at the concentrations
used in the study. Although at the highest concentrations
the proteasome inhibitor MG132 effectively decreased the
survival of the cells, its clinically licensed functional
homologue, bortezomib, was not effective.
An alternative way to calculate relationship between the in
vitro drug concentrations and the in vivo used values is to
use the area under curve (AUC) values of the individual
drugs. To compare AUC values with the RMAPC data the
following formula was used:
in vitro used concentration (µg/ml) × 72 h/AUC (µgxh/
ml) in vivo.
In vivo AUC levels from the literature are summarized in
Table 1. Using the formula for representing the mean cell
survival curves for all the drugs along a common "ratio of
AUC" axis, carboplatin, methotrexate and dactinomycin
showed higher efficacy in comparison to RMAPC figures
whereas the sensitivity order for the other drugs or for the
group classifications did not change.
Discussion
The presented data suggest that many EBV transformed B-
cell lines share a common cytotoxic drug sensitivity pro-
file independent of their origin. This profile does not
change even after many years of in vitro culturing. EBV
appears to be the necessary and sufficient etiological agent
behind the malignant immunoblastic B-cell lymphopro-
liferations in immunosuppressed patients. In all these
cases the EBV encoded, latency associated viral proteins
drive the cell proliferation without any obvious need for
additional genetic changes. The phenotype of these
tumors closely resembles the in vitro growing LCLs and the
experimentally induced tumors that appeared upon intra-
peritoneal implantation of LCLs into SCID mice [11].
Considering the phenotypic and karyotypic stability of
EBV transformed B-cells, our data raises the hope that
PTLDs, AIDS associated CNS lymphomas and XLP associ-
ated lymphoproliferations may show similar patterns of
drug sensitivity as the ones that we have established in the
present study on a cohort of diverse LCLs.
Sugimoto et al. suggested that EBV mediated transforma-
tion is a two step process where, after prolonged passage,
the cells may become aneuploid, accumulate p53 muta-
tions, down regulate the p16/retinoblastoma protein
Drug sensitivity of LCLs for anthracyclines, vinca alkaloids and taxansFigure 3
Drug sensitivity of LCLs for anthracyclines, vinca alkaloids 
and taxans.Page 9 of 12
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inoculation into nude mice [7]. Some of the cell lines that
we have examined were kept in continuous culture over
five years (IARC171, LSspontan, 980215). These cells are
still euploid and show low soft agar clonability. The oldest
line IARC171, has wild type p53, is non-tumorigenic
upon subcutan inoculation but produces generalized
immunoblastic lymphomas in SCID mice after intraperi-
toneal inoculation. The findings that PTLD can arise very
rapidly in post-transplant patient together with the data
that freshly EBV infected B-cells can grow into generalized
immunoblastic lymphomas within a few weeks, implies
that the development of PTLD does not require aneu-
ploidy. Sawada et al. reported that LCLs with negative or
low telomerase activity and normal karyotypes are more
sensitive against certain drugs, than LCLs with a high tel-
omerase activity and abnormal karyotypes [22]. This data
together with our present findings may suggest that rap-
idly emerging PTLDs may show different drug sensitivity
pattern from EBV positive aneuploid diffuse large cell B-
cell lymphomas that arise for example in AIDS patients in
sub-Saharan Africa.
Our data shows that euploid LCLs are particularly sensi-
tive for anti-microtubule drugs and anthracyclines.
Although all LCLs showed a dose dependent increase of
cytotoxicity when treated with different members of these
two drug families, only vincristine and paclitaxel as well
as epirubicin and doxorubicin were considered to be
effective when the used in vitro drug concentrations were
compared to the maximum achievable plasma concentra-
tions.
Alkylating agents, such as cyclophosphamide and
ifosphamide were not effective on LCLs. This might be
explained by the fact that both of these compounds are
Drug sensitivity mean values of 17 lymphoblastoid cell lines plotted against the Ratio of Maximum Achieved Plasma Concentra-tion (RMAPC) valuesFigure 4
Drug sensitivity mean values of 17 lymphoblastoid cell lines plotted against the Ratio of Maximum Achieved 
Plasma Concentration (RMAPC) values. The different drug families are labelled with different colours. The highly effec-
tive (Group 1) and partially effective (Group 2) drugs are identified.Page 10 of 12
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lites by the liver in vivo. Prednisolone was active but only
in very high concentrations.
Conclusion
Vincristine and methotrexate are included in the fre-
quently used CHOP and VAPEC-regimes, but no data
could be found for the clinical use of epirubicin and pacl-
itaxel for the treatment of PTLD or other EBV induced
lymphoproliferations. Our results suggest that the inclu-
sion of epirubicin and paclitaxel into chemotherapy pro-
tocols against PTLD may be justified.
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